Navigation Links
Children with HIV/AIDS falling through the cracks of treatment scale-up efforts
Date:12/1/2011

[Geneva/New York, 1 December 2011] Less than one-quarter (23%) of children with HIV/AIDS who need treatment are getting it, according to a report released by the World Health Organization (WHO) on the occasion of World AIDS Day (1 December 2011). Although treatment coverage for adults has been steadily climbing and has now reached approximately half of those in need, coverage for children is lagging far behind, highlighted the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organization that has recently launched a new paediatric HIV drug development programme.

'Children with HIV/AIDS are falling through the cracks', said Dr Bernard Pcoul, Executive Director of the DNDi. '250,000 children died of HIV-related complications in 2010 that's nearly 700 each day. This is simply unacceptable.'

There are several reasons for this situation including lack of access for pregnant women to antenatal care, HIV testing, and antiretrovirals (ARVs) to prevent mother-to-child transmission and treat expecting mothers, as well as difficulties diagnosing HIV in infants. But one of the most important, and overlooked, is the lack of suitable formulations of ARVs adapted for children, particularly babies and toddlers. The reason for this neglect lies, ironically, with the success of the virtual elimination of HIV among newborns in wealthy countries.

'There's little profit to be made from developing treatments for the millions of children with HIV/AIDS, 90% of whom are the poorest of the poor in sub-Saharan Africa, and the lack of market incentive means pharmaceutical companies do not develop ARVs adapted to their needs', Dr Pcoul continued. 'Without treatment, half of the children born with HIV die before their second birthday.'

WHO recommends immediate ART for all HIV-positive children less than two years old, but the safety and correct dosing have not been established in very young children for the majority of ARVs approved for adults. In addition, key existing paediatric ARV formulations taste bad, require impractical multiple liquid preparations and refrigeration, and have undesirable interactions with tuberculosis (TB) drugs.

DNDi's new paediatric HIV programme aims to develop an improved first-line therapy for children under three years of age. Ideally, this ARV combination therapy needs to be easy to administer and better tolerated by children than current drugs, as well as heat stable and easily dispersible (dissolvable in water or breast milk). It must also carry minimal risk for developing resistance and require minimum weight adjustments. Finally, any new formulations must be compatible with TB drugs.

'Given the current funding crisis, we are deeply concerned that children with HIV/AIDS who are already invisible and largely voiceless will fall even further down on the agenda', said Dr Marc Lallemant, Head of DNDi's Paediatric HIV Programme. 'And while everything possible needs to be done to achieve the long-term goal of "eliminating" new infections among infants, including through scale-up of prevention of mother-to-child transmission programmes, a more serious response is urgently needed for HIV-positive children today.'


'/>"/>

Contact: Violaine Dllenbach
vdallenbach@dndi.org
41-794-241-474
Drugs for Neglected Diseases Initiative
Source:Eurekalert

Related medicine news :

1. Food served in childrens hospitals rated largely unhealthy
2. Functional brain pathways disrupted in children with ADHD
3. Dana-Farber/Childrens Hospital Boston study identifies possible therapy for radiation sickness
4. Drug laws fail to protect children
5. Acupuncture Safe for Children, Review Finds
6. Ill-Fitting Childrens Seat Belts Common in U.S., Study Finds
7. Young Chimps Play Much Like Children Do
8. Study identifies silent stroke risk factors for children with sickle cell anemia
9. AAOS issues new clinical practice guideline for treating common elbow fractures in children
10. Children experience differing changes one year after a siblings death from cancer
11. Flu Hits 90 Million Children Under 5 Each Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... GA (PRWEB) , ... February 08, 2016 , ... Coast ... cavity-free. February is National Children’s Dental Health Month and family dentist Yvonne Dorrian, DMD, ... p.m. at Coast Dental , located next to Target at 1207 North Peachtree ...
(Date:2/8/2016)... ... 08, 2016 , ... The Valentine’s Season is famous for gift giving with flowers, chocolates and ... are loved. This year, for more than 5.6 million Americans suffering with Alzheimer’s, those ... enough to remind them of the lives they’ve led and the people they’ve touched. ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... case packer for pouches, bags, and flow wrapped products at WestPack 2015, February ... specialty product manufacturers step up to semi-automatic or fully-automatic case packing with a ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... expansion into Canada to provide its range of unique and advantaged protective ... Quebec City that will provide bilingual customer service and marketing support. A new ...
(Date:2/8/2016)... ... February 08, 2016 , ... The Bell Agency, ... the latest beneficiary of their ongoing community enrichment program. The current campaign fundraises ... schools. Donations are now being accepted at: http://www.angelsanddoves.com/donate.html . , Angels & ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... 2016 Cardiovascular Surgery Devices - Medical ... Medical Devices sector report, "Cardiovascular Surgery Devices - ... of Cardiovascular Surgery Devices currently in pipeline stage. ... The report provides comprehensive information on the pipeline ... various stages of development. The report reviews major ...
(Date:2/8/2016)... TOKYO and FAIRFIELD, N.J. ... (Otsuka) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) today announced that ... exclusive development and commercialization rights for OPA-15406 in the ... agreement also provides manufacturing rights.  OPA-15406 is a topical, ... for atopic dermatitis. --> ...
(Date:2/8/2016)... February 8, 2016 --> ... research report "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, ... Management, Cosmetic Surgery, Ophthalmology, Gynecology) - Global Forecasts to ... market over the forecast period of 2015 to 2020. ... 2020, at CAGR of 10.5% from 2015 to 2020. ...
Breaking Medicine Technology: